Pear Therapeutics raises $64 million

After receiving FDA last month for its prescription software to treat opioid addiction, Pear Therapeutics has posted $64 million in new fundraising.

The reSET-O prescription digital therapeutic for opioid use disorder consists of a 12-week cognitive behavioral therapy program along with outpatient treatment. It includes buprenorphine, a standard medication for opioid addiction, while helping to reinforce positive behaviors through interactive therapy lessons…

Lilly to acquire Loxo Oncology

Lilly has confirmed that it will acquire targeted cancer drug maker Loxo Oncology for $8 billion. This will give the Indianapolis based company the TRK inhibitor Vitrakvi, the first drug approved by the FDA to target tumors according to a genetic abnormality rather than the location of the cancer.

This comes just days after Bristol-Myers Squibb announced its $74 billion acquisition of Celgene.

Bayer restructuring

Bayer announced last week that it will close its hemophilia manufacturing facility in Wuppertal, Germany, and lay off 350 workers. Its recombinant factor VIII production will take place at its site in Berkeley, California. The cuts in Germany come on top of the announced layoffs in October of more than 225 manufacturing workers in Berkeley.

Sandoz recalls losartan products

The first of a series of recalls involving blood pressure medication were in August. Months later, tainted drugs continue to be found in the US supply. The FDA and Sandoz have announced the recall of one lot of losartain blood pressure medicine that was manufactured by its Lek Pharmaceuticals unit in Ljubljana, Slovenia, because it contains N-nitrosodiethylamine (NDEA), a suspected carcinogen.

NDEA along with N-Nitrosodimethylamine (NDMA) are two probable human carcinogens that the FDA has discovered can be created during manufacturing under certain conditions.

Click here to view the entire article.

Regeneron’s Eylea generates over $1 billion in quarterly US sales

The third quarter US sales for Regeneron’s Eylea were listed as $1.02 billion. This is the first time the drug has generated over $1 billion in quarterly US sales. Q2 sales were $992 million. In August, Eylea received an FDA nod in wet age-related macular degeneration as a 12-week dosing formulation, and the agency is scheduled to decide on the drug’s use in diabetic retinopathy by May 13, 2019.